Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Water and Proteins Inside Cells: Sloshing Around, Or Not? | Main | Selective Scaffolds »

December 9, 2009

Drug Companies Since 1950

Email This Entry

Posted by Derek

There's a data-rich paper out in Nature Reviews Drug Discovery on the history of drug innovation in the industry. I'll get to its real conclusions in another upcoming post, but some of the underlying data are worth a post of their own.

The author (Bernard Munos of Lilly) looks at new drug approvals (NMEs) since 1950, and finds:

At present, there are more than 4,300 companies that are engaged in drug innovation, yet only 261 organizations (6%) have registered at least one NME since 1950. Of these, only 32 (12%) have been in existence for the entire 59-year period. The remaining 229 (88%) organizations have failed, merged, been acquired, or were created by such M&A deals, resulting in substantial turnover in the industry. . .Of the 261 organizations, only 105 exist today, whereas 137 have disappeared through M&A and 19 were liquidated.

At the high end of the innovation scale, 21 companies have produced half of all the NMEs that have been approved since 1950, but half of these companies no longer exist. . .Merck has been the most productive firm, with 56 approvals, closely followed by Lilly and Roche, with 51 and 50 approvals, respectively. Given that many large pharmaceutical companies estimate they need to produce an average of 2–3 NMEs per year to meet their growth objectives, the fact that none of them has ever approached this level of output is concerning.

Indeed it is - either those growth targets are unrealistic, or the number of new drugs thought to be needed to support them has been overestimated, or we're all in some trouble. Speculation welcomed - I lean toward the growth targets being hyped up to please investors, but I'm willing to be persuaded.

And the fact that most of the new drugs come from a much smaller list of companies should be no surprise - that looks like a perfect example of a power law (aka "long tail") effect. Given the way research works, I'd actually be surprised if it were any other way.Now about that figure of 4,300 companies, though: what could possibly be on it? All sorts of startups that I've never heard of, of course - but how can that account for such a large number?

It appears to come from this PDF, where it appears on slide 114 (whew). There's no listing, just a breakdown of 1450 companies in the US, 450 in Canada, 1600 in Europe, and 740 in the Asia/Pacific region. Anyone want to hazard any guesses about how real those numbers are?

Comments (18) + TrackBacks (0) | Category: Business and Markets | Drug Industry History


COMMENTS

1. Wavefunction on December 9, 2009 11:45 AM writes...

It's interesting to see the author citing Nassim Taleb's "The Black Swan"!

Permalink to Comment

2. Hap on December 9, 2009 1:42 PM writes...

I don't know if that's interesting or ominous...

I wonder how many of the approved drugs were purchased from smaller companies - while the number given of pharmaceutical companies that have existed or do exist seems high, maybe fewer of them achieved nothing than it seems if some of the drugs approved from other companies were sold to them by smaller companies.

Permalink to Comment

3. Biobug on December 9, 2009 2:01 PM writes...

I did some similar analysis for a company about 1.5 years ago. I identified 530 public companies that trade in the US (so it includes some ex-US), and around 250 to 300 viable US based private companies. Both numbers likely shrank in the last financial crises, and they include diagnostics along with generic companies, pharma companies, and biotech. The public company number includes medical devices but the private number does not, and both numbers exclude medtech, insurance, hospitals, PBMs, etc etc.

The Burrill numbers seem a tad high to me, they may be including other healthcare fields, and they may not have filtered for companies that have no substantive operations. VCs are especially good at failing to mention or remove from their websites those companies that fail or are nothing but some IP collecting dust under a name.

Permalink to Comment

4. Ed on December 9, 2009 2:17 PM writes...

Nice typo on p.22 of that pdf from the life science experts at Burrill and Co. :-)

Permalink to Comment

5. David P on December 9, 2009 2:32 PM writes...

Thanks for the heads up on this article, interesting (and, as Hap says, ominous) stuff.

Not sure about 4,300 companies: my question is what counts? A start-up with 2 people and an idea? Something a bit more developed than that? If the former, I am amazed it is only 4000.

Permalink to Comment

6. Hap on December 9, 2009 4:06 PM writes...

Sorry. I haven't read the article, so I don't know how ominous the article is as a whole - I just figured that references to "The Black Swan" don't tend to mean anything good and either imply imminent catastrophe or that something neglected has the potential to cause catastrophe.

Permalink to Comment

7. Mark on December 9, 2009 4:07 PM writes...

I'm thinking the same thing as comment #2.

I wonder how the compounds were counted. If a company was purchased, were all of its marketed products attributed to the company that acquired them?

Take a look at Pfizer's numbers from 2000 to 2009. It looks like about 8-10 NMEs were approved. But how many NME's did Pfizer actually produce in-house in that period? I can't think of many: Viagra, Chantix, Selzentry, ? ? ? ?.

Mark

Permalink to Comment

8. cliffintokyo on December 10, 2009 3:25 AM writes...

#6 Hap,

Far too clever for most people; why don't you spell it out?
I can think of several neglected major-league issues that could potentially lead to Teva being the only pharmaceutical company left standing and making products that both physicians and patients trust....

Permalink to Comment

9. Petros on December 10, 2009 4:54 AM writes...

Pfizer's inhouse NMEs launched since 2000

eletriptan (Relpax) 2001
Ziprasidone (Geodon) 2001
Fosfluconazole (Prodif) 2003 Japan only
varenicline (Chantix) 2006
maraviroc (Selzentry) 2007

Permalink to Comment

10. RB Woodweird on December 10, 2009 7:27 AM writes...

There is no way of telling whether the trends in the business since 1950 are ominous or typical unless some the numbers from some other industries are given for comparison.


Organic chemistry, graduate school, vengeful ghosts, high explosives. What could possibly go wrong?
http://www.amazon.com/Novel-Efficient-Synthesis-Cadaverine/dp/1448627176

Permalink to Comment

11. Jordan on December 10, 2009 12:04 PM writes...

1450 companies in the US and 450 in Canada? Canada only has 10% of the population of the USA. Seems fishy to me.

Permalink to Comment

12. Druggist on December 10, 2009 12:38 PM writes...

I don't think the number of 4,300 companies is unreasonable....I work in competitive intelligence and we are tracking over 3,500 active companies with at least one defined drug development project. Of course, many of these are very early-stage start-ups. We don't track generics firms, which would bump up our numbers considerably if we did.

Vast majority are in the US, followed by UK, Japan, Switzerland and then Canada.

Permalink to Comment

13. Ed on December 10, 2009 12:52 PM writes...

Surprised Germany isn't on that list Druggist - where does das Bundesrepublik come in at?

Permalink to Comment

14. Anonymous on December 10, 2009 1:00 PM writes...

Yeah...ignore my last post...was counting drugs per country not companies per country. Hence Switzerland being so high (the Novartis effect).

It's actually USA, then Canada, Japan, then Germany and France (almost tied) and the UK.

Permalink to Comment

15. Ed on December 10, 2009 1:05 PM writes...

And now I'm surprised that France beats out the UK (given the number of French chemists that come to the UK to find work!)

Permalink to Comment

16. SteveM on December 10, 2009 6:05 PM writes...

If you extract out the me-too drugs with marginal additional clinical value from the success count, the innovation picture becomes even less impressive.

Moreover, under a more stringent future cost containment paradigm, the Nexiums and Pristiqs of the new product world may never see the light of day. So the pipelines may be even more shallow.

Permalink to Comment

17. Sumontro on December 11, 2009 6:59 PM writes...

Why would these companies have so few innovations? I thought drug companies spend a LOT on research.

Permalink to Comment

18. Mutatis Mutandis on December 13, 2009 5:41 PM writes...

They spend a LOT on research, but they do it with dumbfounding inefficiency. I think the fundamental cause is very simple, which makes the repetition of the error even sadder.

Modern drug discovery research is an incredibly complex process, which requires great attention to a large number of factors, and a complex blending of skills. The number of requirements that have to be met is large, or if you prefer to put it the other way, the number of possible causes for failure is vast. The average success rate is dismal. For the lucky people, success may come by being incredibly talented; for most of us success depends on learning from our (numerous) errors and gradually adjusting our ideas and teams until we arrive at something that works.

The fundamental problem is that this concept is very hard to sell to the management of a large pharma company. For one reason or another, often on the advice of some consultant who knows next to nothing about the drug industry, management reaches instead for an endless series of golden bullets. According to these modern day snake-oil sellers, you will inevitably be successful if only you screen at least a million compounds, or if you look for natural compounds, or if you gamble everything on biologicals, or if you invest in fragment-based screening, or if you do drug design by cheminformatics, or if you do phenotypical screening and systems biology, or if you gamble on portfolio management and process excellence, and so on. Most of us have seen too many of these waves come and go to remember all of them.

Often these things have real value, although at least equally often management grasps for straws that are rooted in very loose soil. But that doesn't matter. The point is that there are no golden bullets, no magical formulas for success, and focussing your investments in one area while neglecting the others is wasteful because the things you neglected invariably come back to bite you. To get a good drug, you have to look at all the facets of the problem simultaneously, and even then you need to be lucky.

(Of course no single person can do that, which is why good teamwork is so important. The kind of reorganization in which pharma specializes, is often madly destructive of good teams.)

But this is not just an industry problem. It is equally true at large academic institutes.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
The Worst Seminar
Conference in Basel
Messed-Up Clinical Studies: A First-Hand Report
Pharma and Ebola
Lilly Steps In for AstraZeneca's Secretase Inhibitor
Update on Alnylam (And the Direction of Things to Come)
There Must Have Been Multiple Chances to Catch This
Weirdly, Tramadol Is Not a Natural Product After All